TC
TCKRF
TECK RESOURCES LTD
$61.63
-1.23%
No data for this timeframe.
Vol
SEC Reports3
Exchange OTC·Sector Mining & Quarrying of Nonmetallic Minerals (No Fuels)·Inc. A1·CIK 0000886986·Prev Close $62.40
Recent Activity
Apr 24, 2026
SEC
Teck Resources Limited reported the voting results from its 2026 Annual Meeting of Shareholders, confirming the election
6-K — Impact 3/10
Apr 23, 2026
SEC
Teck Resources reported strong Q1 2026 results driven by record copper sales, higher commodity prices, and operational s
6-K — Impact 8/10
Apr 23, 2026
SEC
Teck Resources Limited announced a quarterly eligible dividend of $0.125 per share on its Class A and Class B shares, pa
6-K — Impact 2/10
Analyst Ratings
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 13, 2015 | JP Morgan | MAINTAIN | Neutral |
Latest Reports
NEUTRAL
6-K
3/10
Teck Resources Limited reported the voting results from its 2026 Annual Meeting of Shareholders, confirming the election
Apr 24, 2026
BULLISH
6-K
8/10
Teck Resources reported strong Q1 2026 results driven by record copper sales, higher commodity prices, and operational s
Apr 23, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
6-K
3/10
Teck Resources Limited reported the voting results from its 2026 Annual Meeting of Shareholders, con
Apr 24, 2026
BULLISH
6-K
8/10
Teck Resources reported strong Q1 2026 results driven by record copper sales, higher commodity price
Apr 23, 2026
NEUTRAL
6-K
2/10
Teck Resources Limited announced a quarterly eligible dividend of $0.125 per share on its Class A an
Apr 23, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $3.2B | 59.1% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $3.8B | 12.3% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $14.3B | 33.2% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $14.1B | -1.4% | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 13, 2015 | JP Morgan | MAINTAIN | — | Neutral |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.